Baird analyst Ben Kallo downgrades Embark Technology (NASDAQ:EMBK) from Outperform to Neutral and lowers the price target from $15 to $3.
Entourage Health’s Starseed Adds Four New Union Groups To Its Medical Cannabis Program
Starseed Medicinal a subsidiary of Entourage Health Corp.